Company profile: Blueberry Therapeutics
1.1 - Company Overview
Company description
- Provider of nanomedicine-enabled topical treatments for dermatological conditions, including antifungal sprays BB2603 for onychomycosis and BB1202 for tinea pedis that enhance drug penetration with lower doses, and BB1511 cream for atopic dermatitis to support skin barrier and reduce inflammation; also conducts clinical trials to test safety and efficacy.
Products and services
- Nanomedicine: Architects nanotechnology-based topical treatments for dermatological conditions, targeting more effective, safer, and easier-to-use products through advanced nanotechnology development
- BB2603: Produces a nanodelivery-enabled topical terbinafine antifungal spray for onychomycosis, enhancing drug delivery through the nail
- BB1202: Builds a low-dose topical antifungal spray for tinea pedis, engineered to improve drug penetration into the skin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Blueberry Therapeutics
Molecular Imprints
HQ: United States
Website
- Description: Provider of nanopatterning systems and solutions for the hard disk drive and semiconductor sectors, with over 100 issued patents covering imprint tools, materials and masks/templates, process technology and imprint-specific device designs; founded in 2001 in Austin, Texas as a University of Texas spin-out.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Imprints company profile →
Topas Therapeutics
HQ: Germany
Website
- Description: Provider of nanoparticle-based therapeutics and the Topas Particle Conjugates platform to induce antigen-specific immune tolerance by harnessing the liver’s tolerogenic power, targeting autoimmune and antigen-driven diseases (including allergies and anti-drug antibodies), with clinical candidates TPM203 (Phase 1) for pemphigus vulgaris and TPM502 (Phase 2) for celiac disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topas Therapeutics company profile →
Paragraf
HQ: United Kingdom
Website
- Description: Provider of graphene-based electronic devices for sensors and diagnostics, produced with contamination-free technology. Offerings include graphene Hall sensors for magnetic, current and position sensing, cryogenic Hall effect sensors, mass-produced electrolyte-gated GFETs for versatile sensing, biosensors, the Multi-Sensor Test Unit for multi-sensor data acquisition, and custom deposition and foundry services using 2D materials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paragraf company profile →
miDiagnostics
HQ: Belgium
Website
- Description: Provider of next-generation point-of-care diagnostic tests and a silicon nanofluidic platform. Offers disposable tests using drops of blood to detect cells, proteins, nucleic acids and small molecules. Products include a <20 min COVID-19 PCR, a <20 min vaginitis test detecting bacterial vaginosis, vulvovaginal candidiasis and trichomonas vaginalis, a <30 min HSV-1&2 CSF test, and the nanoFluidic Processor (nFP).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full miDiagnostics company profile →
Semblant
HQ: United Kingdom
Website
- Description: Provider of nanotechnology solutions for the electronics industry, innovating and deploying nanomaterials to protect electronic devices from liquid ingress, corrosion, and other damage; backed by a broad range of fundamental patents and offered in submicron thicknesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semblant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Blueberry Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Blueberry Therapeutics
2.2 - Growth funds investing in similar companies to Blueberry Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Blueberry Therapeutics
4.2 - Public trading comparable groups for Blueberry Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →